Analysts await Vital Therapies, Inc. (NASDAQ:VTL) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.32 EPS, up 93.75% or $0.3 from last year’s $-0.62 per share.

At the moment 6 analysts are watching Vital Therapies, Inc. (NASDAQ:VTL), 1 rate it “Buy”, 0 “Outperform”, 4 “Underperform”, 1 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 3 analysts have a mean sales target of 0.00 million. For the quarter ending Sep-16, 3 analysts have a mean sales target of 0.00 million whilst for the year ending Dec-16, 5 analysts have a mean target of 0.00 million.

In terms of earnings per share, 6 analysts have a -0.29 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 6 analysts have a -0.31 EPS mean target and for the quarter ending Sep-16 there are 6 estimates of -1.58 EPS.

The biggest institutional shareholders in Vital Therapies, Inc. include Fidelity Management and Research Company which owns 3 million shares in the company valued at $13.29 million. KCK Ltd is the second biggest holder with 2 million shares currently valued at 26.89 million whilst RS Investment Management Co. LLC has 2 million shares valued at 24.99 million.

Total shares held by institutions as of the most recent company filings are 12,225,258 with a reported 3,788,007 bought and 41,951 sold. These holdings make up 40.12% of the company’s outstanding shares.

Currently insiders hold 497,728 shares in the business which makes up 1.63% of shares. The biggest holder currently is Dr. Terence E. Winters who owns 186,966 shares (0.61% of those outstanding), whilst Errol R. Halperin holds 89,417 (0.29% of shares outstanding) and Mr. Douglas Godshall holds 69,375 (0.23% of shares outstanding).

The stock decreased 0.24% or $0.02 during the last trading session, hitting $14.00. Vital Therapies, Inc. (NASDAQ:VTL) has risen 43.21% over the past 6 months and is uptrending.